Newsroom

News & events

Tout News Press release
Press release
PHAXIAM announces the validation of a new investigator-initiated phase 2 study, PHAGOSCARPA, in the treatment of extra-cavitary vascular grafts implant infection caused by Staphylococcus aureus in which the company will be involved

Sponsored by Assistance Publique – Hôpitaux de Paris (AP-HP) as part of the hospital-based clinical research program (PHRC)

Read more
Press release
PHAXIAM Provides Business and Financial Update For the First Half of 2024

Webinar (in French) today, September 25, 2024 at 6:00 pm CEST Click here to attend

Read more
Press release
Share capital increase : Result Press release

Read more
Press release
Share capital increase : Launch Press release

Read more
Press release
RESULTS OF THE COMBINED GENERAL MEETING OF 28 JUNE 2024

The shareholders approved all the resolutions on which the Board of Directors recommended a favorable vote

Read more
Press release
PHAXIAM Therapeutics announces the success of its rights issue of €7.8m

Following the subscription period, which closed on June 25, 2024, total demand amounted to approximately 3.9 million shares, representing approximately €7.8 million, i.e. a subscription rate of around 77.1%:

Read more
Press release
PHAXIAM Therapeutics launches a rights issue of approximately €10m, which may be increased up to approximately €11.5m if the extension clause is exercised in full, in order to accelerate the implementation of its clinical strategy

Webinar (in French) on June 18, 2024, at 6:00 pm : Register here

Read more
Press release
PHAXIAM announces the availability of the preparatory documents  for the Combined General Meeting of 28 June 2024

Shareholders of PHAXIAM are invited to attend the Combined General Meeting to be held on 28 June 2024 at 9:30 a.m. at the Company’s registered office at 60 avenue Rockefeller – 69008 Lyon (France).

Read more
Press release
PHAXIAM provides Business and Financial Update for the First Quarter of 2024

Webinar (in French) today, May 15, 2024, at 6.00 pm CEST

Read more
News
PHAXIAM Therapeutics announces enrolment of the first patient in the phase 1 study for the treatment of endocarditis infections caused by Staphylococcus aureus

Read more
Press release
Monthly information related to total number of voting rights and shares composing the share capital – March 29, 2024

Read more
News
PHAXIAM Therapeutics announces filing of its 2023 Universal Registration Document (URD) 

Read more

Contact
our team

Journalist, investor, healthcare professional, partner or candidate... if you have any questions about PHAXIAM, please do not hesitate to contact our teams.

Contact us